Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.
First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.
Horizon Space Acquisition I Signs $2B M&A Deal with ArcheNova Biotech Corp.
Horizon Space Acquisition I Corp. (HSPO), a SPAC, has entered into a definitive business combination agreement with clinical-stage biopharmaceutical company ArcheNova Biotech Corp. The transaction values ArcheNova at an implied enterprise value of $2.0 billion. Upon closing, the combined entity, ArcheNova Technology Co., Ltd, is expected to list on the Nasdaq Stock Market.
Eightco Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on August 5, 2026, and Nasdaq has now officially closed the matter.
Newton Golf Company received a Staff Determination letter from Nasdaq on October 6, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders’ equity requirement. As a result, the company's common stock faces suspension and delisting unless it successfully appeals the decision. The company intends to request a hearing before a Nasdaq Hearings Panel to stay the suspension and seek continued listing.
iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.
Skydance M&A Deal with Warner Bros. Discovery, Inc.
Skydance Corporation (formerly Paramount Skydance Corporation) completed its acquisition of Warner Bros. Discovery, Inc. (WBD) on October 6, 2026. In connection with the closing, the company is executing exchange and tender offers for WBD's outstanding senior notes and distributed warrants to its Class B stockholders as a dividend.
Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.
GigCapital8 Corp. has entered into a definitive merger agreement to acquire Quantisimo Corp. through a multi-step merger process involving a new holding company, Quantisimo Holdings Corp. (PubCo). As part of the transaction, WISeQey and SealSQ will contribute their equity interests in several operating subsidiaries, including Miraex SA and SEALCOIN AG, to Quantisimo prior to the closing.
Strategy Inc raised $21.0 million in net proceeds through the sale of 125,183 shares of Class A Common Stock under its at-the-market (ATM) offering program between October 5 and October 11, 2026. The proceeds were used to fund the acquisition of 250 bitcoin, bringing the company's total holdings to 848,250 BTC. Additionally, the company repurchased $192.4 million of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) during the same period.
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) provided a status update regarding its pending merger with Electra Vehicles, Inc. (ELECTRA AI) by announcing a new three-year partnership between Electra and Westbrook Racing. Electra has been selected as the Official Battery Intelligence Partner for the racing team, deploying its AI Brain for Batteries platform starting with the 2026 UIM E1 World Championship season.
Innventure's subsidiary, Accelsius, upgraded its Springdale facility in Austin, Texas, to multi-megawatt power capacity to test next-generation AI liquid cooling systems at megawatt-class rack densities. The company also announced it will expand its lease footprint at the facility by 18,000 square feet in January 2027 to support hyperscale customer validation programs.
Kenvue Signs $7B M&A Deal with Kimberly-Clark Corporation
Kenvue Inc. entered into a supplemental indenture to amend existing senior notes in connection with its pending acquisition by Kimberly-Clark Corporation. The amendments, which eliminate restrictive covenants and reporting requirements, are tied to an exchange offer where Kimberly-Clark will issue up to $7 billion in new notes to replace Kenvue's existing debt.
Kimberly Clark Signs $7B M&A Deal with Kenvue Inc.
Kimberly-Clark announced the early tender results of its offers to exchange up to $7.0 billion of Kenvue Inc. notes for new Kimberly-Clark notes and cash. The exchange offers and related consent solicitations are part of Kimberly-Clark's previously announced pending acquisition of Kenvue. The requisite consents were received to amend the Kenvue indenture, with the acquisition expected to close in the fourth quarter of 2026.
Getty Images entered into a restructuring support agreement (RSA) to implement a comprehensive recapitalization through a prepackaged Chapter 11 plan of reorganization. The deal includes a $533 million equity commitment from the Getty Family and Koch Equity Development, the retirement of senior unsecured notes for $170.2 million in cash, and the conversion of existing equity into 100% ownership for the majority shareholders, taking the company private.
TTM Technologies delivered record Q2 2026 results, beating guidance and raising full-year revenue and EPS outlooks driven by massive AI data center demand and defense growth.
FormFactor entered into a Securities Purchase Agreement with Teradyne, Inc. for a $300 million strategic equity investment via a private placement of 2,234,887 shares of common stock. The transaction is part of a broader technology collaboration aimed at accelerating semiconductor testing for AI, high-performance computing, and advanced packaging applications.
ADC Therapeutics entered into securities purchase agreements for a $86.6 million private placement (PIPE) involving the sale of 12.9 million common shares and 48.1 million pre-funded warrants. The financing included participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. Proceeds will be used to fund ZYNLONTA pipeline studies and extend the company's cash runway into 2029.
IonQ delivered record Q2 revenue of $80.1M, up 287% YoY, while closing the $1.8B Skywater acquisition to become a vertically integrated quantum platform.
TTM Technologies announced a $400 million incremental investment to expand manufacturing capacity across four facilities in China and its facility in Penang, Malaysia. The expansion uses a "rapid-ramp" brownfield approach to scale advanced interconnect technology for AI data center infrastructure and hyperscalers. This investment is in addition to the company's previously disclosed $1.2 billion commitment for the 2025-2029 period.
Humana Partnership with BlackRock, Inc. Worth $2.8B
Humana entered into a new strategic joint venture with BlackRock to manage and operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake held by Welsh, Carson, Anderson & Stowe (WCAS) for approximately $2.8 billion, providing Humana with a lower cost of capital and enhanced balance sheet efficiency by removing existing put option liabilities.
IonQ has entered into a definitive agreement to acquire Elisity, Inc., a Zero Trust security company, in an all-stock transaction valued at up to $1.3 billion including earnouts. The deal consists of $1.15 billion in closing consideration plus up to $150 million in revenue-based earnout consideration through January 2028. The acquisition aims to combine IonQ's quantum cryptography capabilities with Elisity's Zero Trust platform to address emerging quantum-era cybersecurity threats.
Value
$1.15B
Counterparty
Elisity, Inc.
“With Elisity and its team as part of IonQ, we will be well positioned to help customers protect critical infrastructure and enterprise networks throughout the transition to the quantum era. As I said first, Q-Day is coming much faster than predicted. IonQ is offering its customers a vertically integrated full-stack quantum platform across quantum computing, networking, sensing and cybersecurity. Just as adding SkyWater Technology expanded IonQ’s capabilities in chip design, fabrication and packaging, Elisity will bring proven enterprise policy enforcement scale and deployment experience to our quantum security strategy and will give IonQ a strong growth platform to serve customers and create value for our shareholders.”
Niccolo de Masi, Chairman and CEO of IonQ
“Our customers need to prioritize post-quantum cryptography initiatives while securing existing assets to keep essential operations running. With IonQ, we will be optimally positioned to partner with them to modernize their crypto-agility programs, accelerate post-quantum cryptography capabilities while advancing their holistic Zero Trust posture and deploy hybrid-cybersecurity solutions today that are prepared for the quantum future.”
Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.
ClearOne, Inc. received a staff determination letter from Nasdaq on October 8, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders' equity requirement. As a result, Nasdaq has determined to delist the company's common stock, though ClearOne intends to appeal this decision before a Nasdaq Hearings Panel to stay the delisting process.
Quetta Acquisition Corporation received a delisting notice from Nasdaq because it failed to complete an initial business combination within the required 36-month period following its IPO. Trading of the company's securities (QETA, QETAR, QETAU) will be suspended on October 14, 2026, and the company expects its securities to transition to the OTC Pink Limited Market.
Gentherm M&A Deal with Modine Manufacturing Company
Gentherm completed the acquisition of Modine Manufacturing Company's Performance Technologies business (SpinCo) through a merger transaction. Modine shareholders received 0.44619 shares of Gentherm common stock for each SpinCo share, resulting in Modine shareholders owning approximately 43.62% of the combined company. The deal establishes Gentherm as a scaled leader in thermal management and precision flow solutions.
Gran Tierra Energy Signs $1.33B M&A Deal with Maurel & Prom
Gran Tierra Energy stockholders approved the sale of the company's Colombian and Ecuadorian businesses to Maurel & Prom for approximately $1.33 billion. The company expects to receive $315 million in net cash proceeds and become debt-free upon the deal's expected closing by December 31, 2026.
Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.
Flyte Aviation, Inc. entered into an agreement with existing investors to sell 2,050 shares of Series C-4 Convertible Preferred Stock for gross proceeds of $2.05 million. The preferred shares are convertible into common stock at a price of $1.00 per share. Additionally, the company reduced the conversion price of all outstanding Series C, Series D, and Series J preferred stock to $1.00 per share.
Streamex Corp. received a deficiency notice from Nasdaq on October 7, 2026, for failing to maintain the minimum bid price of $1.00 per share over 30 consecutive business days. The company has until April 5, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least ten consecutive business days. The notice does not have an immediate effect on the listing of the company's common stock (STEX).